Primary sclerosing cholangitis

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

Retrieved on: 
Wednesday, October 5, 2022

Details of the virtual presentation:

Key Points: 
  • Details of the virtual presentation:
    The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF).
  • Those interested in registering for the KOL sessions should contact their RBC sales representative.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter , LinkedIn , Facebook and YouTube .

EQS-News: Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022

The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunics business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to managements and employees participation in scientific and industry conferences.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022

Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.

Key Points: 
  • Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and industry conferences.
  • Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, September 27, 2022

The restricted stock units were granted as an inducement material to the employees acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The restricted stock units were granted as an inducement material to the employees acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over a four-year period, subject to the employees continued service with Albireo through the applicable vesting dates.
  • The restricted stock units are subject to the terms and conditions of Albireos 2020 Inducement Equity Incentive Plan.
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

Retrieved on: 
Tuesday, September 20, 2022

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.

Key Points: 
  • BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.
  • Ron Cooper, President and Chief Executive Officer of Albireo, will be presenting on September 28, 2022, at 8:30 AM ET.
  • A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com .
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.

EQS-News: Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Retrieved on: 
Tuesday, September 20, 2022

Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.

Key Points: 
  • Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • These favorable results allowed a smooth transition to the MAD part of the trial.
  • Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • The unblinded data from the single and multiple ascending dose parts of our phase 1 clinical trial of IMU856 in healthy human subjects revealed a favorable safety, tolerability and pharmacokinetic profile.

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

Retrieved on: 
Thursday, September 15, 2022

Prior to Agilent, Dr. Knobil served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences.

Key Points: 
  • Prior to Agilent, Dr. Knobil served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences.
  • Dr. Knobil currently serves on the Board of Marker Therapeutics and previously served on the Board of Arena Pharmaceuticals, prior to its acquisition by Pfizer.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter , LinkedIn , Facebook and YouTube .

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Retrieved on: 
Tuesday, September 13, 2022

GNS561 has completed pre-clinical studies and a Phase 1b trial confirming the rationale for targeting cholangiocarcinoma.

Key Points: 
  • GNS561 has completed pre-clinical studies and a Phase 1b trial confirming the rationale for targeting cholangiocarcinoma.
  • Dr Mark Yarchoan, Associate Professor of Oncology at John Hopkins Medicine (Baltimore, MD) commented: Cholangiocarcinoma is a rare cancer with a high mortality rate.
  • This is why new therapies are urgently needed and is one of the reasons that GNS561 was granted Orphan Drug Designation by the FDA.
  • There is a real path forward for new options for second line treatment in cholangiocarcinoma, and GNS561 represents a strong second-line therapy candidate and hope to patients.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, September 12, 2022

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, September 1, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a positive safety review of the ongoing INTEGRIS-IPF Phase 2a trial of PLN-74809 at 320 mg once-daily dose in patients with idiopathic pulmonary fibrosis (IPF) from a regularly scheduled meeting of its independent Data Safety Monitoring Board (DSMB). The DSMB recommended the INTEGRIS-IPF trial continue without modification.

Key Points: 
  • Interim 12-week data from the 320 mg dose cohort from this Phase 2a, randomized, double-blind, placebo-controlled trial are expected in early 2023.
  • This positive safety review marks an important milestone in the development of PLN-74809.
  • Given 320 mg is the highest dose planned to be tested in the PLN-74809 program, the positive DSMB review significantly builds on the favorable safety profile seen to date, said ric Lefebvre, M.D., Chief Medical Offer at Pliant.
  • In July, Pliant announced positive topline data from the INTEGRIS-IPF trial of 40 mg, 80 mg and 160 mg 12-week dose cohorts.